VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
VERTEX PHARMACEUTICALS INC / MA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$501.95+2.21 (+0.44%)
Close on Oct 19, 2026
- Market cap
- $128.10B
- P/E (TTM)
- 29.2
- Dividend yield
- –
Share price
+$85.14 (+20.43%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
VERTEX PHARMACEUTICALS INC / MA grew revenue 10.2% to $12.59B over the twelve months to Jun 30, 2026. Operating income rose 21.8% to $4.78B, moving the operating margin from 34.4% to 38.0%. Free cash flow was $3.80B, up 8.5% from a year earlier.
Revenue
$12.59B
+10.2% vs. a year earlier
Operating income
$4.78B
+21.8% vs. a year earlier
Free cash flow
$3.80B
+8.5% vs. a year earlier
EPS, diluted
$17.18
+22.4% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $128.10B
- P/E ratio
- 29.2
- Price to sales
- 10.18
- Price to book
- 6.33
- Dividend yield
- –
- Free cash flow yield
- 2.96%
Fundamentals
- Revenue
- $12.59B
- Net income
- $4.41B
- EPS, diluted
- $17.18
- Free cash flow
- $3.80B
- Book value per share
- $79.34
- Diluted shares
- 255M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$12.59B+10.2% YoY
Gross profit
$10.82B+10.1% YoY
Operating income
$4.78B+21.8% YoY
Net income
$4.41B+21.1% YoY
EPS, diluted
$17.18+22.4% YoY
Free cash flow
$3.80B+8.5% YoY
Reported periodTrailing twelve months